A comparison of PK/PD dose response characteristics of glargine in type 2 diabetics.

Trial Profile

A comparison of PK/PD dose response characteristics of glargine in type 2 diabetics.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Vanderbilt University
  • Most Recent Events

    • 31 Jul 2015 Actual Patient number changed from 14 to 20,Treatment arms changed from 5 to 1,time frame for Primay end point (Glucose Infusion Rate )is changed from 1year to 24 hours as reported by ClinicalTrials.gov record.
    • 14 Jun 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 31 Mar 2010 Results published in Diabetes Care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top